DCC-3116 for Solid Tumors
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, DCC-3116, alone and with other drugs, in patients with advanced cancers that have specific genetic mutations. The drug works by blocking a pathway that helps cancer cells grow.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial. Specifically, you must not have taken strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein, including some herbal medications, within 14 days or 5 times the medication's half-life. Additionally, you must stop taking grapefruit products 14 days before starting the study.
What data supports the effectiveness of the drug DCC-3116 for solid tumors?
Research shows that binimetinib, a component of the treatment, is effective in treating melanoma with specific genetic mutations. Additionally, combining BRAF and MEK inhibitors, like binimetinib and trametinib, has shown positive results in treating certain lung cancers, suggesting potential effectiveness in other solid tumors.12345
What safety information is available for DCC-3116 and related treatments?
What makes the drug combination of DCC-3116, Binimetinib, Sotorasib, and Trametinib unique for treating solid tumors?
This drug combination is unique because it targets multiple pathways involved in tumor growth and survival, potentially offering a more comprehensive approach to treating solid tumors compared to single-agent therapies. Each component, like Sotorasib, which targets a specific mutation in cancer cells, adds a layer of specificity and potential effectiveness.910111213
Eligibility Criteria
Adults with advanced solid tumors having specific mutations (RAS/MAPK pathway) who've had certain prior treatments can join. They need good organ function, an ECOG score of 0-2, and must not be pregnant or breastfeeding. Contraception is required for both men and women.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
DCC-3116 is administered in escalating doses as monotherapy and in combination with other drugs to determine the maximum tolerated dose
Expansion
DCC-3116 is administered in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Binimetinib (MAPK Pathway Inhibitor)
- DCC-3116 (MAPK Pathway Inhibitor)
- Sotorasib (MAPK Pathway Inhibitor)
- Trametinib (MAPK Pathway Inhibitor)
Binimetinib is already approved in United States, European Union, Canada, Japan for the following indications:
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation